Xencor, Inc.

Erik Weiking Pong

John R Desjarlais

Matthew J Bernett

Gregory Alan Lazar

Sher Bahadur Karki

Seung Yup Chu

Eugene Alexander Zhukovsky

John O Richards

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Optimized antibodies that target CD19

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells

Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.

Growing community of inventors

Temple City, CA, United States of America

Erik Weiking Pong